Lung cancer remains a formidable global health challenge that necessitates inventive
strategies to improve its therapeutic outcomes. The conventional treatments, including …

Metabolic derivatives of numerous microorganisms inhabiting the human gut can participate
in physiological activities and immune status of the lungs through the gut-lung axis. The …

Objective This study aimed to investigate the causal relationship between mitochondrial
biological function and lung cancer, including its subtypes, via MR. Methods SNPs …

In the last few years, nivolumab has become the standard of care for advanced-stage lung
cancer patients. Unfortunately, up to 60% of patients do not respond to this treatment. In our …

Objective Increasing studies have highlighted the potential utility of non-invasive prognostic
biomarkers in advanced lung cancer patients receiving immune checkpoint inhibitor (ICI) …

Simple Summary The therapeutic scenario of early-stage (ES) non-small cell lung cancer
(NSCLC) is rapidly evolving. Precision medicine, including both targeted therapy and …

Lung cancer has been established as the second most common cancer worldwide (most
common cancer in men and second most common cancer in women) and as the leading …

Simple Summary This observational, single-center, retrospective study aimed to describe
the real-world (RW) healthcare resource utilization (HCRU) among patients with advanced …

Background The data on immune checkpoint inhibitors (ICI) use in lung cancer individuals
generally underrepresented in clinical trials are limited. We aimed to examine the ICI …

CI: 0.60–0.86). The other primary endpoint was OS and this was also met with data of 14.0
vs. 11.7 months (HR: 0.77; 95% CI: 0.65–0.92) respectively. Based on these data …